Merck follows Opdivo’s suit, prices Keytruda in China at half its U.S. tag

When Bristol-Myers Squibb unveiled its price for Opdivo in China, industry watchers considered it a benchmark against which future immuno-oncology therapies will look to for their pricing strategies.

Now it appears at least its arch rival, Merck & Co., has taken note for PD-1 competitor Keytruda.